Mylanta One Antacid/Anti-Gas

Description

Mylanta One Antacid/Anti-Gas chewable tablets are formulated to provide relief from heartburn and gas discomfort. Each tablet combines three active ingredients to deliver both antacid and anti-gas effects in a single dose. The tablets are presented in a berry ginger flavor, designed for a smooth and soothing taste experience. The product is packaged in a plastic bottle containing 50 single-dose chewable tablets, ensuring convenient access for users.

Uses and Indications

This drug is indicated for the relief of heartburn, acid indigestion, and sour stomach. It is also effective in alleviating upset stomach associated with these symptoms, as well as relieving pressure and bloating commonly referred to as gas. Additionally, this drug provides relief from discomfort due to overindulgence in food and drink.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 12 years and older are instructed to chew 1 tablet as symptoms occur, or as directed by a healthcare professional. The maximum allowable dosage is 6 tablets within a 24-hour period. It is important to note that the maximum dosage should not be utilized for more than 2 consecutive weeks.

For children under 12 years of age, consultation with a healthcare professional is recommended prior to use.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

Patients should consult a healthcare professional prior to use if they have a history of kidney disease or are on a magnesium-restricted diet. These conditions may necessitate special consideration and monitoring during treatment.

It is also advisable for patients to seek guidance from a doctor or pharmacist if they are currently taking any prescription medications. Antacids have the potential to interact with certain prescription drugs, which could affect their efficacy or lead to adverse effects.

In the event of an overdose, immediate medical assistance should be sought. Patients are encouraged to contact a poison control center without delay at 1-800-222-1222 for further instructions and support.

Patients should remain vigilant for any adverse reactions and discontinue use if they experience any concerning symptoms, subsequently contacting their healthcare provider for further evaluation.

Side Effects

Patients should be aware of potential adverse reactions associated with the use of this medication. It is important to consult a healthcare professional before use if there is a history of kidney disease or if the patient is on a magnesium-restricted diet, as these conditions may influence the safety and efficacy of the treatment.

Additionally, patients are advised to seek guidance from a doctor or pharmacist if they are currently taking any prescription medications. Antacids have the potential to interact with certain prescription drugs, which may lead to altered therapeutic effects or increased risk of adverse reactions.

While specific side effects were not detailed in the provided information, the importance of monitoring for any unexpected reactions during treatment cannot be overstated. Patients should report any unusual symptoms or concerns to their healthcare provider promptly.

Drug Interactions

Antacids may interact with various prescription medications, potentially affecting their absorption and efficacy. It is advisable to monitor the timing of antacid administration in relation to other medications to minimize these interactions. Specifically, antacids should be taken at least 2 hours apart from other drugs to ensure optimal therapeutic outcomes.

Packaging & NDC

Below are the non-prescription pack sizes of Mylanta One Antacid/Anti-Gas (calcium carbonate, magnesium hydroxide, dimethicone). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a healthcare professional before use. For adolescents aged 12 years and older, the recommended dosage is to chew 1 tablet as symptoms occur or as directed by a healthcare provider.

The maximum dosage for this age group is 6 tablets within a 24-hour period. It is important to note that this maximum dosage should not be used for more than 2 weeks.

Geriatric Use

Elderly patients should consult a healthcare provider prior to use if they have kidney disease, as this may affect the safety and efficacy of the treatment. Additionally, it is advisable for geriatric patients to seek guidance from a doctor or pharmacist if they are currently taking any prescription medications, as antacids may interact with certain drugs.

For adults and children aged 12 years and older, the recommended dosage is to chew 1 tablet as symptoms occur or as directed by a healthcare professional. It is important for elderly patients to adhere to the maximum dosage limit of 6 tablets within a 24-hour period and to avoid using the maximum dosage for more than 2 weeks. For children under 12 years of age, consultation with a healthcare provider is necessary before use.

Healthcare providers should closely monitor geriatric patients for any adverse effects or interactions, particularly in those with pre-existing conditions or those taking multiple medications.

Pregnancy

There are no specific warnings, precautions, or dosage modifications associated with the use of Mylanta One Antacid/Anti-Gas during pregnancy. The prescribing information does not indicate whether the product is contraindicated in pregnant patients or if there are any known risks to the fetus. As such, healthcare professionals should consider the absence of data when advising women of childbearing potential regarding the use of this product during pregnancy.

Lactation

There are no specific warnings or recommendations regarding the use of Mylanta One Antacid/Anti-Gas in lactating mothers. The available information does not address the potential for excretion in breast milk, the risk to breastfed infants, or any special considerations for lactation.

Renal Impairment

Patients with renal impairment should consult a healthcare professional prior to use, particularly if they have a history of kidney disease. It is essential to assess renal function and consider potential dosing adjustments or monitoring requirements based on the degree of impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should implement supportive care measures, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs.

Additionally, it is recommended to consult local poison control centers or relevant toxicology resources for guidance on specific management protocols and antidotes, if applicable.

Documentation of the incident, including the substance involved, estimated dose, and time of exposure, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a poison control center at 1-800-222-1222 in the event of an overdose. It is important for patients to understand the seriousness of an overdose and the necessity of prompt action to ensure their safety.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a temperature range of 20-25°C (68-77°F) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept within the specified temperature limits to prevent degradation.

Additional Clinical Information

The medication is administered orally. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Mylanta One Antacid/Anti-Gas, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)